Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 9, 2005, Pages 31-41

  Griffiths, Roland R ^a   Johnson, Matthew W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT;

ALCOHOL INTOXICATION; ALGORITHM; ANOREXIA; ANXIETY DISORDER; COGNITIVE DEFECT; CONCEPT FORMATION; DEPERSONALIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ABUSE PATTERN; DRUG CYTOTOXICITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HUMAN; INSOMNIA; IRRITABILITY; MEMORY DISORDER; MUSCLE TWITCH; NAUSEA; PARESTHESIA; PHOTOPHOBIA; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSIS; REBOUND; REVIEW; SEIZURE; SUBSTANCE ABUSE; TREMOR; WITHDRAWAL SYNDROME;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPNOTICS AND SEDATIVES; PSYCHOPHARMACOLOGY; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SELF MEDICATION; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 29444461026     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. National Institutes of Health, NIH Consensus Development Program. NIH state-of-the-science conference statement on manifestations and management of chronic insomnia in adults. June 13-15, 2005. Available at: http://consensus. nih.gov/2005/2005InsomniaSOS026html. htm. Accessed Sept 28, 2005
2. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals: implications for problems of long-term use and abuse. Psychopharmacology (Berl) 1997;134:1-37
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
4. Barnas C, Rossmann M, Roessler H, et al. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. J Clin Psychopharmacol 1992;12:397-402
5. Gelkopf M, Bleich A, Hayward R, et al. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend 1999;55:63-68
6. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001;63:1-22
7. Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005;19:195-204
8. Mintzer MZ, Griffiths RR. Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability. Drug Alcohol Depend 1998;53:49-66
9. Johnston LD, O'Malley PM, Bachman JG, et al. Overall teen drug use continues gradual decline; but use of inhalants rises. University of Michigan News and Information Services: Ann Arbor, Mich. Dec 21, 2004. Available at: www.monitoringthefuture.org. Accessed Aug 5, 2005
10. Substance Abuse and Mental Health Services Administration. Results from the 2003 National Survey on Drug Use and Health: National findings. Rockville, Md; 2004. Office of Applied Studies, NSDUH Series H-25, DHHS Publication No. SMA 04-3964
11. Baiter MB, Uhlenhuth EH. Unpublished survey results.
12. Cited by: Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992;44:151-347
13. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002;63:817-825
14. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-799
15. Ancoli-Israel S, Richardson GS, Mangano RM, et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005;6:107-113
16. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 1999;9(suppl 6): S399-S405
17. Jindal RD, Buysse DJ, Thase ME. Maintenance treatment of insomnia: what can we learn from the depression literature? Am J Psychiatry 2004;161:19-24
18. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 2003;70: S13-S40
19. Griffiths RR, Lamb RJ, Ator NA, et al. Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 1985;9:133-151
20. Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 2003;70:S55-S72
21. Griffiths RR, Bigelow GE, Henningfield JE. Similarities in animal and human drug-taking behavior. In: Advances in Substance Abuse, Behavioral and Biological Research, vol 1. Greenwich, Conn: JAI Press, Inc; 1980:1-90
22. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 2003;70:S41-S54
23. Griffiths RR, Wolf B. Relative abuse potential of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990;10:237-243
24. Iguchi MY, Handelsman L, Bickel WK, et al. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend 1993;32:257-266
25. Jaffe JH, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004;99:165-173
26. Fraser HF, Jasinski DR. The assessment of the abuse potentiality of sedative/hypnotics (depressants) (methods used in animals and man). In: Martin WR, ed. Drug addiction-I Morphine, Sedative/Hypnotic and Alcohol Dependence. New York: Springer-Verlag; 1977:589-612
27. Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 1987;39:251-413
28. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl 1998;393:95-101
29. Gatzonis SD, Angelopoulos EK, Daskalopoulou EG, et al. Convulsive status epilepticus following abrupt high-dose benzodiazepine discontinuation. Drug Alcohol Depend 2000;59:95-97
30. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology (Berl) 1999;144:220-233
31. Preston KL, Wolf B, Guarino JJ, et al. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. J Pharmacol Exp Ther 1992;262:707-720
32. Johnson MW, Suess PE, Griffiths RR. Dose effect comparison of ramelteon and triazolam: abuse potential and behavioral effects. Presented at the 67th annual meeting of the College of Problems on Drug Dependence; June 18-23, 2005; Orlando, Fla
33. American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine Dependence, Toxicity, and Abuse. Washington, DC: American Psychiatric Association; 1990
34. Longo LP, Johnson B. Addiction, pt 1: benzodiazepines-side effects, abuse risk and alternatives. Am Fam Physician 2000;61. Available at: http://www.aafp.org/afp/20000401/2121.html. Accessed Aug 9, 2005
35. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry 2004;65:151-155
36. Physicians' Desk Reference. 59th ed. Montvale, NJ: Thompson PDR; 2005
37. Jindal RD, Buysse DJ, Thase ME. Dr. Jindal and colleagues reply [letter]. Am J Psychiatry 2004;161:1723
38. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health, 2002 and 2003. Rockville, Md; 2005. Office of Applied Studies, NSDUH. Available at: http://oas.samhsa.gov/nhsda/2k3tabs/toc. htm#DU. Accessed Aug 8, 2005
39. Hajak G, Bandelow B, Zulley J, et al. "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia-assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 2002;14:1-7